No interaction between factor V Leiden and hyperhomocysteinemia of MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study

Thrombosis and Haemostasis

Volumn 97, Issue 1, 2007, Pages 32-37

  Kiejzer, Miranda B A J ^a   Borm, George F ^a   Blom, Henk J ^a   Bos, Gerard M J ^b   Rosendaal, Frits R ^c   den Heijer, Martin ^a,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Leiden University Medical Center ^*  (Netherlands)

Author keywords

Case control; Case only; Factor V Leiden; Homocysteine; Meta analysis; Methylenetetrahydrofolatereductase; MTHFR; VITRO

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE MUTATION; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MEDLINE; PRIORITY JOURNAL; PROTEIN INTERACTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOGENICITY; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

FACTOR V; GENOTYPE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ODDS RATIO; RISK; VENOUS THROMBOSIS;

EID: 33846976525     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-09-0486     Document Type: Article

References (41)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
2. Rothman KJ, Greenland S. Modern Epidemiology. Lippincott-Raven 1998.
3. Koeleman BPC, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
4. Zöller B, Berntsdotter A, de Frutos PG, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
5. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
6. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
7. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-9.
8. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
9. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
10. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22.
11. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002; 325: 1202-8.
12. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: Meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002; 32: 51-8.
13. Undas A, Williams EB, Butenas S, et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276: 4389-97.
14. Keijzer MBAJ, den Heijer M, Blom HJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88: 723-8.
15. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
16. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
17. De Stefano V, Zappacosta B, Persichilli S, et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol 1999; 106: 564-8.
18. Tsai AW, Cushman M, Tsai MY, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 2003; 72: 192-200.
19. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Prevalence and risk assessment. Arterioscler Thromb Vase Biol 1999; 19: 511-8.
20. Cattaneo M, Chantarangkul V, Taioli E, et al. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999; 93: 1-8.
21. Grossmann R, Schwender S, Geisen U, et al. CBS 844ins68, MTHFR TT677 and EPCR 4031ins23 genotypes in patients with deep-vein thrombosis. Thromb Res 2002; 107: 13-5.
22. Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998; 103: 42-4.
23. Kluijtmans LAJ, den Heijer M, Reitsma PH, et al. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-8.
24. 20210 mutation. Thromb Haemost 1998; 79: 907-1.
25. Alhenc-Gelas M, Arnaud E, Nicaud V, et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-10.
26. Akar N, Akar E, Misirlioglu M, et al. Search for genetic factors favoring thrombosis in Turkish population. Thromb Res 1998; 92: 79-82.
27. Akar N, Akar E, Akçay R, et al. Effect of metylene-tetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res 2000; 97: 163-7.
28. Cappucci G, Margaglione M, Ames PRJ. Comparative prevalence of antiphospholipid antibodies and thrombophilic genotypes in consecutive patients with venous thrombosis. Blood Coagul fibrinolysis 2001; 12: 659-65.
29. 506). Arterioscler Thromb Vase Biol 1997; 17: 1662-6.
30. Iglesias Varela ML, Adamczuk YP, Forastiero RR, et al. Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism. Thromb Res 2001; 104: 317-24.
31. den Heijer M, Willems H, Blom H, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomised, placebo-controlled, double blind trial. Blood September 7, 2006; doi:10.1182/blood-2006-04-014654.
32. Willems HPJ, Bos GMJ, Gerrits WBJ, et al. Acidic citrate stabilizes blood samples for assay of total homocysteine. Clin Chem 1998; 44: 3425.
33. Te Poele-Pothoff MT, van den Berg M, Franken DG, et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995; 32: 218-20.
34. Hosmer DW. Lemeshow S. Confidence Interval estimation of interaction. Epidemiology 1992; 5: 452-6.
35. Zarychanski R, Houston DS. Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability. Thromb Haemost 2004; 91: 1115-22.
36. Ahlbom A, Alfredsson L. Interaction: A word with two meanings creates confusion. Fur J Epidemiol 2005; 20: 563-4.
37. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. New Engl J Med 1996; 334: 763-8.
38. Kalkanoǧlu HS, Coşkun T, Aydoǧdu SD, et al. Factor V Leiden mutation in Turkish patients with homozygous cystathionine β-synthase deficiency. J Inherit Metab Dis 2001; 24: 367-9.
39. Quere I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene. New Engl J Med 1996; 335: 289-90.
40. Kluijtmans LAJ, Boers GHJ, Verbruggen B, et al. Homozygous cystathionine ß-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood 1998; 91: 2015-8.
41. Yap S, O'Donnell KA, O'Neill C, et al. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency. Thromb Haemost 1999; 81: 502-5.